First patient dosed in Ph 1b study of iadademstat in ES-SCLC
Dr. Carlos Buesa, Oryzon’s CEO, stated: “The initiation of this investigator-led study at Yale University represents an important milestone in our efforts to expand the clinical development of iadademstat in small cell lung cancer. Combining LSD1 inhibition with immunotherapy and radiotherapy is a compelling strategy, and we look forward to the insights this trial may provide into the potential role of iadademstat in addressing this aggressive disease with high unmet medical need.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.